GlassScriptPhysician profile
Ashley Marie Bock
NPI 1538402540
$8,185.99
in general payments reported to CMS, 2019-2025
20 companies · $894 in 2025
The $894 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2021: $414 · 2022: $954 · 2023: $3,915 · 2024: $1,901 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068 · Honoraria: $2,750 · Travel and Lodging: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.25 |
| Honoraria | $2,750.00 |
| Travel and Lodging | $891.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,480.22 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $3,414.40 | 2022-2024 | Impella |
| Pfizer INC. | $370.73 | 2022-2025 | |
| Edwards Lifesciences Corporation | $240.30 | 2022-2025 | |
| Livanova USA, INC. | $178.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $119.68 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.18 | 2021-2024 | Lifevest |
| Medtronic, INC. | $68.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.31 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $28.17 | 2021-2023 | Farxiga |
| Cvrx, INC. | $26.33 | 2021 | |
| Inspire Medical Systems, INC. | $22.77 | 2023 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $19.68 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $15.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2025 | |
| Boston Scientific Corporation | $13.31 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $12.80 | 2022 | |
| Altathera Pharmaceuticals LLC | $9.84 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.